The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Unanswered questions in frontline CLL treatment
Ian Flinn, MD, PhD, Tennessee Oncology, Nashville, TN, describes unresolved issues in the field of frontline treatment for chronic lymphocytic leukemia (CLL). Time-limited therapy is now becoming more prevalent in the frontline setting, but different approaches exist, such as a one size fits all approach outlined in the CLL14 trial (NCT02242942) and a minimal residual disease (MRD) testing-based approach. Dr Flinn highlights how data from the CAPTIVATE trial (NCT02910583) will improve frontline treatment for CLL. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
